Why the study?
Previous findings linking diabetes mellitus to cisplatin-induced nephrotoxicity during short hydration were secondary and lacked appropriate power calculation, prompting evaluation in a real-world setting.
Does baseline diabetes mellitus increase the incidence of cisplatin-induced nephrotoxicity in lung cancer patients receiving short hydration method?
Does baseline diabetes mellitus increase the incidence of cisplatin-induced nephrotoxicity in lung cancer patients receiving short hydration method?
Baseline diabetes mellitus significantly increases the risk of cisplatin-induced nephrotoxicity in lung cancer patients receiving short hydration therapy.
DM complications may warrant enhanced CIN monitoring during cisplatin short hydration; leaves open prospective validation before protocol changes.
Cisplatin (CDDP)-induced nephrotoxicity (CIN) is dose-limiting. We revealed that co-administration of non-steroid anti-inflammatory drugs and baseline comorbidity of diabetes mellitus (DM) are associated with CIN development in the short hydration method; however, the results were accessorily obtained without appropriate power calculation. This study aimed to demonstrate the influence of DM complications on CIN incidence in a real-world setting. Lung cancer patients receiving CDDP (≥ 75 mg/m2)-containing regimens with a short hydration method (n = 227) were retrospectively evaluated. The patients were divided into control and baseline DM complication groups. The primary endpoint was the evaluation of CIN incidence between the groups. Propensity score-matching was performed to confirm the robustness of the primary analysis results. CIN occurred in 6.8% of control and 27.0% of DM patients, respectively, with a significant difference in all-patient populations (P = 0.001). In addition, variation of serum creatinine and creatinine clearance significantly worsened in DM patients. Similar results were obtained in a propensity-matched population. Multivariate logistic regression analysis found that DM complication is a singular risk factor for CIN development (adjusted odds ratio; 4.31, 95% confidence interval; 1.62–11.50, P = 0.003). In conclusion, our study revealed that baseline DM complications significantly worsen CIN.
No takes yet. Share an insight, caveat, or question.
Saito et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: